I would not give this postmenopausal woman adjuvant with a recurrence score of 10 based on RxPONDER trial. In that trial women with recurrence scores of 25 or less were randomized to receive chemotherapy + endocrine versus endocrine therapy alone. The Kaplan Meier curves were superimposable. I would...

I think this is a complicated situation that requires a nuanced approach. We know that clinicopathological features are important, independent of Oncotype RS. I would need to consider age (she is postmenopausal, but there is a difference between a 52-year-old and a 75-year-old), grade, tumor size, %...

I would not recommend adjuvant chemotherapy for a postmenopausal woman with 1-3 nodes based on RxPONDER. With an Oncotype of 10, this is an endocrine-sensitive tumor that has favorable prognosis and the key is to start endocrine therapy and plan for extended duration, don’t stop at 5 years for...

While Oncotype DX Recurrence Score (ODX-RS) has prognostic and predictive value regarding adjuvant chemotherapy, recent studies have shown the clinical distinctiveness in BRCA1/2–driven early breast cancers or invasive lobular breast cancers, as well as the age being an important factor. There...